Ipilimumab + Nivolumab + Relatlimab for Melanoma

This trial explores how ctDNA (tiny bits of cancer DNA found in blood) can guide the best initial treatment for people with advanced melanoma. Participants will receive a combination of medications, including nivolumab and relatlimab (both immunotherapy drugs), to determine if these can slow cancer progression. If ctDNA levels change, some patients might also receive ipilimumab (another immunotherapy drug) in addition to their treatment. Those with advanced melanoma that cannot be surgically removed and who have detectable ctDNA might be suitable candidates for this trial. As a Phase 4 trial, this study involves treatments already FDA-approved and proven effective, aiming to understand how they can benefit more patients.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot be on certain immunosuppressive medications or anti-tumor therapies beyond the standard of care regimens. It's best to discuss your specific medications with the trial team.

Research has shown that using nivolumab and relatlimab together is generally safe for treating advanced melanoma. Studies found that serious side effects occur in about 21% of patients, which is 10% more than with nivolumab alone. However, this combination is already approved for treating advanced melanoma, indicating that its safety is well understood.

Research from the RELATIVITY-048 study demonstrated that the combination of ipilimumab, nivolumab, and relatlimab is both safe and effective. Although adding ipilimumab can increase the risk of immune-related side effects, this triple combination is approved for advanced melanoma. This approval indicates that the safety risks are known and managed in medical settings.

Researchers are excited about using nivolumab, relatlimab, and ipilimumab for melanoma because they bring a fresh approach to tackling the disease. While traditional treatments like surgery, radiation, and chemotherapy focus on directly removing or killing cancer cells, these drugs harness the body's immune system to fight the melanoma. Nivolumab and relatlimab work by blocking specific proteins that prevent immune cells from attacking cancer, effectively unleashing the immune system's full potential. Ipilimumab, on the other hand, boosts immune activity by targeting a different protein, CTLA-4, which further amplifies the body's ability to fight off cancer. This combination of treatments could potentially offer a more powerful and sustained response against melanoma compared to standard therapies.

Research has shown that using nivolumab with relatlimab can significantly delay the progression of advanced melanoma. Studies found that patients on this combination treatment had stable disease for an average of 10.2 months, compared to 4.6 months for those taking nivolumab alone. In this trial, participants in Cohort A and one arm of Cohort B will receive nivolumab and relatlimab. For overall survival, 52% of patients treated with nivolumab and ipilimumab, a similar therapy, were alive after five years. Additionally, relatlimab has demonstrated similar effectiveness to ipilimumab in treating melanoma. In this trial, some participants in Cohort B and Cohort C will receive a combination of nivolumab, relatlimab, and ipilimumab. These findings suggest that combining nivolumab with relatlimab, or adding ipilimumab, could help manage melanoma more effectively, giving patients more time without disease progression.²³⁴⁶⁷